These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24762619)

  • 1. Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer.
    Ji Y; Zhang Z; Nie K; Lan K; Geng C; Liu S; Zhang L; Zhang Z; Sun L; Zou X
    Chin Med J (Engl); 2014; 127(8):1600. PubMed ID: 24762619
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.
    Asai N; Yamaguchi E; Kubo A
    Clin Lung Cancer; 2014 May; 15(3):e33-5. PubMed ID: 24702855
    [No Abstract]   [Full Text] [Related]  

  • 3. Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.
    Watanabe N; Nakahara Y; Taniguchi H; Kimura T; Kondoh Y; Kataoka K; Sakamoto K
    Acta Oncol; 2014 Jan; 53(1):158-60. PubMed ID: 23750540
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease.
    Tachihara M; Kobayashi K; Ishikawa Y; Hori S; Tamura D; Otera H; Funada Y; Nishimura Y
    Jpn J Clin Oncol; 2014 Aug; 44(8):762-4. PubMed ID: 24872405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.
    Tamiya A; Okamoto I; Miyazaki M; Shimizu S; Kitaichi M; Nakagawa K
    J Clin Oncol; 2013 Jan; 31(1):e15-7. PubMed ID: 23169500
    [No Abstract]   [Full Text] [Related]  

  • 6. Esophageal Ulcer in a Lung Cancer Patient. Crizotinib-induced Esophageal Injury.
    Sawada T; Maeno K; Joh T
    Gastroenterology; 2015 Aug; 149(2):e6-7. PubMed ID: 26123560
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
    Yoneshima Y; Okamoto I; Takano T; Enokizu A; Iwama E; Harada T; Takayama K; Nakanishi Y
    Lung Cancer; 2015 Jun; 88(3):349-51. PubMed ID: 25837798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.
    Mirshahidi HR; Mirshahidi S
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):375-85. PubMed ID: 25797684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
    Gastaud L; Ambrosetti D; Otto J; Marquette CH; Coutts M; Hofman P; Esnault V; Favre G
    Lung Cancer; 2013 Nov; 82(2):362-4. PubMed ID: 24001942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review.
    Créquit P; Wislez M; Fleury Feith J; Rozensztajn N; Jabot L; Friard S; Lavole A; Gounant V; Fillon J; Antoine M; Cadranel J
    J Thorac Oncol; 2015 Aug; 10(8):1148-55. PubMed ID: 26200268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib.
    Park J; Yoshida K; Kondo C; Shimizu J; Horio Y; Hijioka S; Hida T
    Lung Cancer; 2013 Sep; 81(3):495-496. PubMed ID: 23891512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crizotinib-induced fatal fulminant liver failure.
    van Geel RM; Hendrikx JJ; Vahl JE; van Leerdam ME; van den Broek D; Huitema AD; Beijnen JH; Schellens JH; Burgers SA
    Lung Cancer; 2016 Mar; 93():17-9. PubMed ID: 26898609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful crizotinib retreatment after crizotinib-induced interstitial lung disease.
    Yanagisawa S; Inoue A; Koarai A; Ono M; Tamai T; Ichinose M
    J Thorac Oncol; 2013 Aug; 8(8):e73-4. PubMed ID: 23857405
    [No Abstract]   [Full Text] [Related]  

  • 16. Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib.
    Ou SH; Azada M; Dy J; Stiber JA
    J Thorac Oncol; 2011 Dec; 6(12):2135-7. PubMed ID: 22088989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib (xalkori) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2012 Feb; 54(1383):11-2. PubMed ID: 22354221
    [No Abstract]   [Full Text] [Related]  

  • 18. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI; Gautschi O
    Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Drug Treats forms of Non-Small Cell Lung Cancer and Thyroid Cancer.
    Aschenbrenner DS
    Am J Nurs; 2020 Sep; 120(9):25. PubMed ID: 32858693
    [No Abstract]   [Full Text] [Related]  

  • 20. Refining the toxicity profile of crizotinib.
    Solomon B
    J Thorac Oncol; 2014 Nov; 9(11):1596-7. PubMed ID: 25436794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.